Prescient Therapeutics Ltd (ASX:PTX) managing director and CEO Steven Yatomi-Clarke is back in the studio to discuss a pivotal agreement with a New York Stock Exchange company. Together with Thermo Fisher Scientific (NYSE:TMO), Prescient is out to develop and commercialise a highly scalable version of its OmniCAR cell therapy platform. The aim is to advance the next generation of OmniCAR cells, which can be produced faster, more efficiently and at a lower cost, and it comes just days after the company inked a manufacturing agreement with Q-Gen Cell Therapeutics. Overall, Yatomi-Clarke said it's great to see "the next domino fall" and that the agreement should result in an improved product and process that can be decentralised and scaled.
Prescient developing "the next generation of OmniCAR cells" with Thermo Fisher Scientific
